Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VGX-3100 + imiquimod
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Small Molecules, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular (VGX-3100, With Electroporation), Topical (imiquimod)
01
Overview
**VGX-3100 + imiquimod** is an investigational combination therapy for the treatment of high-grade squamous intraepithelial lesion (HSIL) of the vulva and related HPV-16 and/or HPV-18-induced precancerous lesions. VGX-3100 is a DNA-based immunotherapy designed to induce cell-mediated immune responses against the E6 and E7 oncoproteins of HPV-16 and HPV-18, delivered intramuscularly with electroporation. Imiquimod is a topical immune response modifier that acts as a toll-like receptor 7 agonist, stimulating local innate and adaptive immunity. The rationale for combining these drugs is to potentiate anti-HPV immune responses and enhance lesion regression, as studied in clinical trials (e.g., NCT03180684) for vulvar HSIL caused by HPV-16/18[1][3][5].
- Other names
- VGX-3100 + imiquimod
02
Targets
TLR7 (Toll-like receptor 7)Human papillomavirus type 18 E6 and E7 proteinsHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on VGX-3100 + imiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VGX-3100 + imiquimod.